SEC Company Response from Theriva Biologics, Inc. (TOVX) (CIK 0000894158) (TOVX) — Oct 4, 2018
Theriva Biologics, Inc. (TOVX) (CIK 0000894158)
Date: Oct. 4, 2018 · CIK: 0000894158 · Accession: 0001144204-18-052521
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-227400
Letter
A.G.P./Alliance Global Partners
590 Madison Avenue
New York, New York 10022
October 4, 2018
VIA EDGAR
U.S. Securities and Exchange Commission
100 F St., NE
Washington, D.C. 20549
RE: Synthetic Biologics, Inc. (the “Company”)
File No. 333-227400
Registration Statement on Form S-1
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, A.G.P./Alliance Global Partners, as representative of the underwriters, hereby joins the request of the Company that the effective date of the above-referenced Registration Statement be accelerated so that it will become effective at 5:00 p.m. Eastern Time on October 9, 2018, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter, who is reasonably anticipated to be invited to participate in the distribution of the securities, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.
Very truly yours,
A.G.P./Alliance Global Partners
Show Raw Text
CORRESP 1 filename1.htm A.G.P./Alliance Global Partners 590 Madison Avenue New York, New York 10022 October 4, 2018 VIA EDGAR U.S. Securities and Exchange Commission 100 F St., NE Washington, D.C. 20549 RE: Synthetic Biologics, Inc. (the “Company”) File No. 333-227400 Registration Statement on Form S-1 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, A.G.P./Alliance Global Partners, as representative of the underwriters, hereby joins the request of the Company that the effective date of the above-referenced Registration Statement be accelerated so that it will become effective at 5:00 p.m. Eastern Time on October 9, 2018, or as soon thereafter as practicable. Pursuant to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter, who is reasonably anticipated to be invited to participate in the distribution of the securities, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus. The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue. Very truly yours, A.G.P./Alliance Global Partners By: Thomas Higgins /s/ Thomas Higgins Name: Thomas Higgins Title: Managing Director